Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $1.88 million. The enterprise value is -$3.29 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 3.58 million shares outstanding. The number of shares has increased by 2,802.98% in one year.
| Current Share Class | 3.58M |
| Shares Outstanding | 3.58M |
| Shares Change (YoY) | +2,802.98% |
| Shares Change (QoQ) | +11.60% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 1.80% |
| Float | 3.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.30 |
| Forward PS | n/a |
| PB Ratio | 0.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of 0.00.
| Current Ratio | 0.66 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.45 |
Financial Efficiency
Return on equity (ROE) is -115.46% and return on invested capital (ROIC) is -23.46%.
| Return on Equity (ROE) | -115.46% |
| Return on Assets (ROA) | -14.93% |
| Return on Invested Capital (ROIC) | -23.46% |
| Return on Capital Employed (ROCE) | -40.18% |
| Weighted Average Cost of Capital (WACC) | 53.81% |
| Revenue Per Employee | $163,074 |
| Profits Per Employee | -$3.11M |
| Employee Count | 5 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, Onconetix has paid $525 in taxes.
| Income Tax | 525 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.19% in the last 52 weeks. The beta is 3.52, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.52 |
| 52-Week Price Change | -95.19% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 35.04 |
| Average Volume (20 Days) | 425,894 |
Short Selling Information
The latest short interest is 37,915, so 1.06% of the outstanding shares have been sold short.
| Short Interest | 37,915 |
| Short Previous Month | 158,751 |
| Short % of Shares Out | 1.06% |
| Short % of Float | 1.16% |
| Short Ratio (days to cover) | 0.10 |
Income Statement
In the last 12 months, Onconetix had revenue of $815,371 and -$15.53 million in losses. Loss per share was -$16.56.
| Revenue | 815,371 |
| Gross Profit | 632,913 |
| Operating Income | -6.34M |
| Pretax Income | -14.03M |
| Net Income | -15.53M |
| EBITDA | -6.33M |
| EBIT | -6.34M |
| Loss Per Share | -$16.56 |
Full Income Statement Balance Sheet
The company has $5.22 million in cash and $48,774 in debt, with a net cash position of $5.17 million or $1.44 per share.
| Cash & Cash Equivalents | 5.22M |
| Total Debt | 48,774 |
| Net Cash | 5.17M |
| Net Cash Per Share | $1.44 |
| Equity (Book Value) | 15.76M |
| Book Value Per Share | 10.11 |
| Working Capital | -3.07M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -9.68M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.68M |
| FCF Per Share | -$2.70 |
Full Cash Flow Statement Margins
| Gross Margin | 77.62% |
| Operating Margin | -778.16% |
| Pretax Margin | -1,720.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Onconetix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,802.98% |
| Shareholder Yield | -2,802.98% |
| Earnings Yield | -827.40% |
| FCF Yield | -515.61% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 13, 2025. It was a reverse split with a ratio of 1:85.
| Last Split Date | Jun 13, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:85 |
Scores
Onconetix has an Altman Z-Score of -8.09 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.09 |
| Piotroski F-Score | 2 |